AI Article Synopsis
- Since 2017, pembrolizumab and avelumab have become standard treatments for metastatic bladder cancer in Europe, with the study focusing on their usage in the Netherlands.
- Out of 1,525 patients diagnosed with metastatic bladder cancer between 2018 and 2021, only about 34.7% received systemic treatment, primarily after first-line chemotherapy.
- Despite the introduction of maintenance avelumab in 2021, the use of immune checkpoint inhibitors has not significantly increased, indicating a need for further research on treatment patterns.
Article Abstract
Unlabelled: Since 2017, two immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of metastatic urothelial carcinoma in Europe: pembrolizumab as second-line therapy and avelumab as maintenance therapy. Our aim was to describe the use of ICIs as first and later lines of treatment in patients with metastatic bladder cancer (mBC) in the Netherlands. We identified all patients diagnosed with primary mBC between 2018 and 2021 in the Netherlands from the Netherlands Cancer Registry (NCR). NCR data were supplemented with data from the Dutch nationwide Prospective Bladder Cancer Infrastructure (ProBCI) collected from medical files, with follow-up until death or end of data collection on January 1, 2023. A total of 1525 patients were diagnosed with primary mBC between 2018 and 2021 in the Netherlands. Of these, 34.7% received at least one line of systemic treatment with chemotherapy or ICI. After first-line platinum-based chemotherapy, 34.1% received second-line ICI and 3.9% received maintenance ICI. Among patients who completed or discontinued first-line cisplatin- or carboplatin-based chemotherapy after approval of maintenance ICI in the Netherlands, 40.7% and 19.7% received second-line ICI, and 9.3% and 14.1% received maintenance ICI, respectively. ICI use for mBC treatment has not increased considerably since their introduction in 2017. Future research should assess whether the introduction of maintenance avelumab (available since April 2021 in the Netherlands) has led to increases in the proportion of patients with mBC patients receiving systemic treatment and the proportion receiving ICI.
Patient Summary: We assessed the rate of immunotherapy use for patients with metastatic bladder cancer in the Netherlands. Since its introduction, immunotherapy has been used in a minority of patients, mostly as second-line treatment after platinum-based chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10776918 | PMC |
| http://dx.doi.org/10.1016/j.euros.2023.11.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle Invasive Bladder Cancer.
Curr Urol Rep
January 2025
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Purpose Of Review: This narrative review aims to report upon the existing treatment evidence and strategies for managing lower urinary tract symptoms (LUTS) during treatment, including transurethral resection and intravesical therapy. This review also attempts to examine novel approaches to mitigate treatment-related lower urinary tract symptoms and improve treatment adherence.
Recent Findings: There is sparse but promising evidence in improving LUTS secondary to intravesical therapy.
Integrating Ultra-High-Performance Liquid Chromatography and Orbitrap High-Resolution Mass Spectrometry, Feature-Based Molecular Networking, and Network Medicine to Unlock Harvesting Strategies for Endangered Sinocalycanthus Chinensis.
J Sep Sci
January 2025
Zhejiang Provincial Key Laboratory of Evolutionary Ecology and Conservation, Taizhou University, Taizhou, China.
Evaluating the practical utility of endangered plant species is crucial for their conservation. Nevertheless, numerous endangered plants, including Sinocalycanthus chinensis, lack historical usage data, leading to a paucity of guidance in traditional pharmacological research. This gap impedes their development and potential utilization.
View Article and Find Full Text PDFEffectiveness of Enfortumab-Vedotin for Right Atrial Metastasis Following Total Cystectomy: A Case Report.
Cureus
December 2024
Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, JPN.
Cardiac metastases from bladder cancer are extremely rare and typically associated with a poor prognosis. We here report a case of a 74-year-old woman who had been diagnosed with multiple bladder cancer and later developed pelvic recurrence and multiple bone metastases. Second-line pembrolizumab treatment achieved complete remission.
View Article and Find Full Text PDFSpatially-resolved analyses of muscle invasive bladder cancer microenvironment unveil a distinct fibroblast cluster associated with prognosis.
Front Immunol
December 2024
Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Muscle-invasive bladder cancer (MIBC) is a prevalent cancer characterized by molecular and clinical heterogeneity. Assessing the spatial heterogeneity of the MIBC microenvironment is crucial to understand its clinical significance.
Methods: In this study, we used imaging mass cytometry (IMC) to assess the spatial heterogeneity of MIBC microenvironment across 185 regions of interest in 40 tissue samples.
Partial cystectomy as a surgical option for colorectal cancer patients with pathological bladder invasion: an original retrospective study.
Therap Adv Gastroenterol
January 2025
Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, 510655, Guangzhou, Guangdong, China.
Background: Limited research exists on colorectal cancer (CRC) patients with bladder invasion, with survival outcomes post-cystectomy underexplored and a debate between partial and total cystectomy ongoing.
Objective: The study aimed to evaluate the effect of pathological bladder invasion on the long-term tumour prognosis of patients with clinically diagnosed bladder invasion in CRC after cystectomy.
Design: Retrospective, cohort study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!